|Bid||0.00 x 900|
|Ask||8.25 x 1000|
|Day's Range||6.33 - 6.51|
|52 Week Range||0.91 - 8.97|
|Beta (5Y Monthly)||2.31|
|PE Ratio (TTM)||4.20|
|Earnings Date||Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.00|
IVERIC bio announced the design of the second pivotal clinical trial for Zimura®, in development for the treatment of GA secondary to dry AMD.
Geographic atrophy is estimated to represent a market opportunity of over $1 billion, with the current patient population at more than 1 million, Nierengarten said in the note. In October, Iveric Bio had announced Zimura showed positive results in slowing the growth of lesions in its Phase 2 study. The company’s lead asset is also being investigated in Stargardt disease and data from this study could come as early as in the back half of 2002, the analyst noted.
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this […]
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
If you're interested in IVERIC bio, Inc. (NASDAQ:ISEE), then you might want to consider its beta (a measure of share...
NEW YORK , Oct. 13, 2019 /PRNewswire/ -- Allegiant Travel Company (ALGT) Lifshitz & Miller announces investigation into possible securities laws in connection with a CBS News 60 Minutes segment criticizing ...
Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Trevena, Inc. (TRVN) ('' Trevena ''). Last year, a class action complaint was filed against Trevena and certain of its officers and directors.